Johnny N Mahlangu (J Mahlangu, Johnny Mahlangu)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 46

Top Topics

Atrial Fibrillation

Drug Administration

Top Venues

Haemophilia : the official journal of the World Federation of Hemophilia

European journal of haematology

Science translational medicine

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Wolfgang A Miesbach, Manuel D Carcao, Johnny N Mahlangu, Yesim Dargaud, Victor Jimenez-Yuste, Cédric Hermans
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia : the official journal of the World Federation of Hemophilia 30 (2) (2024)
Johnny N Mahlangu, Saliou Diop, Michelle Lavin
Diagnosis and treatment challenges in lower resource countries: State-of-the-art. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Wolfgang A Miesbach, Manuel D Carcao, Johnny N Mahlangu, Yesim Dargaud, Victor Jimenez-Yuste, Cédric Hermans
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia : the official journal of the World Federation of Hemophilia 30 (2) (2024)
Kevin W Doxzen, Jennifer E Adair, Yris Maria Fonseca-Bazzo, Daima Bukini, Kenneth Cornetta, Varsha Dalal, Renato Luiz Guerino-Cunha, Suradej Hongeng, Geeta Jotwani, Cissy Kityo-Mutuluuza, Krishnamurti Lakshmanan, Johnny N Mahlangu, Julie Makani, Vikram Mathews, Margareth Castro Ozelo, Savita Rangarajan, Janine Scholefield, João Batista Silva Júnior, Joseph M McCune
The translational gap for gene therapies in low- and middle-income countries. Science translational medicine 16 (746) (2024)
Jerzy Windyga, Shashikant Apte, Melissa Frei-Jones, Teruhisa Fujii, Chuhl Joo Lyu, Laura Villarreal Martinez, Jameela Sathar, Oleksandra Stasyshyn, Huyen Tran, Nadezhda Zozulya, Renée Brown Frandsen, Jesper Skov Neergaard, Jay Jay Thaung Zaw, Johnny N Mahlangu
Disease and treatment burden of patients with haemophilia entering the explorer6 non-interventional study. European journal of haematology (2024)
Wolfgang A Miesbach, Manuel D Carcao, Johnny N Mahlangu, Yesim Dargaud, Victor Jimenez-Yuste, Cédric Hermans
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Johnny N Mahlangu, Saliou Diop, Michelle Lavin
Diagnosis and treatment challenges in lower resource countries: State-of-the-art. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Kevin W Doxzen, Jennifer E Adair, Yris Maria Fonseca-Bazzo, Daima Bukini, Kenneth Cornetta, Varsha Dalal, Renato Luiz Guerino-Cunha, Suradej Hongeng, Geeta Jotwani, Cissy Kityo-Mutuluuza, Krishnamurti Lakshmanan, Johnny N Mahlangu, Julie Makani, Vikram Mathews, Margareth Castro Ozelo, Savita Rangarajan, Janine Scholefield, João Batista Silva Júnior, Joseph M McCune
The translational gap for gene therapies in low- and middle-income countries. Science translational medicine 16 (746) (2024)
Johnny N Mahlangu, Saliou Diop, Michelle Lavin
Diagnosis and treatment challenges in lower resource countries: State-of-the-art. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Wolfgang A Miesbach, Manuel D Carcao, Johnny N Mahlangu, Yesim Dargaud, Victor Jimenez-Yuste, Cédric Hermans
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Johnny N Mahlangu, Saliou Diop, Michelle Lavin
Diagnosis and treatment challenges in lower resource countries: State-of-the-art. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Gili Kenet, Thomas Moulton, Brian M Wicklund, Sanjay P Ahuja, Miguel A Escobar, Johnny N Mahlangu
Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials. Journal of blood medicine 14 (2023)
Ulrike M Reiss, Johnny N Mahlangu, Tsukasa Ohmori, Margareth Castro Ozelo, Alok Srivastava, Lei Zhang
Haemophilia gene therapy-Update on new country initiatives. Haemophilia : the official journal of the World Federation of Hemophilia (2022)
David C Rees, Yurdanur Kilinc, Selma Unal, Carlton D Dampier, Betty S Pace, Banu Kaya, Sara Trompeter, Isaac Odame, Johnny N Mahlangu, Sule Unal, Julie Brent, Regine Grosse, Beng R Fuh, Baba Psalm Duniya Inusa, Ariel Koren, Goksel Leblebisatan, Carina Levin, Elizabeth McNamara, Karin Meiser, Douglas Hom, Stephen J Oliver
A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood 139 (17) (2022)
Miguel A Escobar, Marlène Beijlevelt, Aleah Loney, Johnny N Mahlangu, Lochana Nanayakkara, Daniela Neme, Gianluigi Pasta, Pierre Toulon, Huyen Tran
World federation of hemophilia international hemophilia training fellowship program: 50 years of enhancing global care. Haemophilia : the official journal of the World Federation of Hemophilia 28 (5) (2022)
Johnny N Mahlangu, Faraizah Abdul Karim, Oleksandra Stasyshyn, Bartosz Korczowski, Blanca Salazar, Samantha Lucas, Amy Suen, Brahm Goldstein, Thomas Chung, Ingrid Pabinger-Fasching
Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study. Research and practice in thrombosis and haemostasis 6 (2) (2022)
Johnny N Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, Daniel R Malan, John Teeter, Robert J Charnigo, Eunhee Hwang, Steven Arkin
Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. British journal of haematology (2022)
Steven W Pipe, Cedric Hermans, Meera Chitlur, Manuel D Carcao, Giancarlo Castaman, Joanna A Davis, Jonathan Ducore, Amy L Dunn, Miguel A Escobar, Janna Journeycake, Osman Khan, Johnny N Mahlangu, Shannon L Meeks, Ismail Haroon Mitha, Claude Négrier, Ulrike Nowak-Göttl, Michael Recht, Tammuella Chrisentery-Singleton, Oleksandra Stasyshyn, Kateryna V Vilchevska, Laura Villarreal Martinez, Michael Wang, Jerzy Windyga, Guy Aaron Young, W Allan Alexander, Daniel Bonzo, Christopher Macie, Ian S Mitchell, Evelyne Sauty, Thomas A Wilkinson, Amy D Shapiro
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia : the official journal of the World Federation of Hemophilia 28 (4) (2022)
Johnny N Mahlangu, Alfonso Iorio, Tami Livnat
Emicizumab state-of-the-art update. Haemophilia : the official journal of the World Federation of Hemophilia (2022)
Mahlatse Mankgele, Ebrahim Variava, Tumelo Moloantoa, Kennedy Otwombe, Khuthadzo Hlongwane, Dineo Disenyane, Meshack Bida, Raylton Chikwati, Tracy Snyman, Neil Martinson, Johnny N Mahlangu
Underdiagnosis of iron deficiency anaemia in HIV-infected individuals: a pilot study using soluble transferrin receptors and intensive bone marrow iron stores to improve the diagnosis. Journal of clinical pathology (2022)
Johnny N Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, Daniel R Malan, Silva Zupančić Šalek, Michael Wang, Lisa N Boggio, Inga Hegemann, Andrzej Mital, Matthew Cardinal, Tong Zhu, Pengling Sun, Steven Arkin
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. British journal of haematology (2022)
Barbara A Konkle, Glenn F Pierce, Donna Coffin, Mayss Naccache, R Cary Clark, Lindsey A George, Alfonso Iorio, Brian O'Mahony, Steven W Pipe, Mark W Skinner, Crystal Watson, Flora Peyvandi, Johnny N Mahlangu, null null
Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of thrombosis and haemostasis : JTH 18 (11) (2021)
Johannes Oldenburg, Huyen Tran, Flora Peyvandi, Ramiro Núñez, Peter Trask, Sammy Chebon, Johnny N Mahlangu, Michaela Lehle, Victor Jimenez Yuste, Sylvia von Mackensen
Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia : the official journal of the World Federation of Hemophilia 27 (3) (2021)
Miguel A Escobar, James Luck, Yevhenii Averianov, Jonathan Ducore, Maria Fernanda López Fernández, Adam Giermasz, Daniel P Hart, Janna Journeycake, Craig M Kessler, Cindy Leissinger, Johnny N Mahlangu, Laura Villarreal Martinez, Wolfgang Miesbach, Ismail Haroon Mitha, Doris Quon, Mark T Reding, Jean-François Schved, Oleksandra Stasyshyn, Kateryna V Vilchevska, Michael Wang, Jerzy Windyga, W Allan Alexander, Ahmad Al-Sabbagh, Daniel Bonzo, Ian S Mitchell, Thomas A Wilkinson, Cédric Hermans
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia : the official journal of the World Federation of Hemophilia 27 (6) (2021)
Christine L Kempton, Peter Trask, Aric Parnes, Markus Niggli, Avrita Campinha-Bacote, Michael U Callaghan, Niamh O'Connell, Ido Paz-Priel, Johnny N Mahlangu
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia : the official journal of the World Federation of Hemophilia 27 (2) (2021)
Mark W Skinner, Claude G Negrier, Ido Paz-Priel, Sammy Chebon, Victor Jimenez Yuste, Michael U Callaghan, Michaela Lehle, Markus Niggli, Johnny N Mahlangu, Amy D Shapiro, Midori Shima, Avrita Campinha-Bacote, Gallia G Levy, Johannes Oldenburg, Sylvia von Mackensen, Steven W Pipe
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia : the official journal of the World Federation of Hemophilia 27 (5) (2021)
Johnny N Mahlangu, Howard Levy, Martin Lee, Frank Del Greco
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. Haemophilia : the official journal of the World Federation of Hemophilia 27 (4) (2021)
Aric D Parnes, Johnny N Mahlangu, Steven W Pipe, Ido Paz-Priel, Michaela Lehle, Peter C Trask, Victor Jimenez Yuste
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia : the official journal of the World Federation of Hemophilia 27 (6) (2021)
Johnny N Mahlangu
Requirements to participate in haemophilia clinical trials. Haemophilia : the official journal of the World Federation of Hemophilia (2021)
Miguel A Escobar, Giancarlo Castaman, Santiago Bonanad Boix, Michael Callaghan, Philippe de Moerloose, Jonathan Ducore, Cédric Hermans, Janna Journeycake, Cindy Leissinger, James Luck, Johnny N Mahlangu, Wolfgang Miesbach, Ismail Haroon Mitha, Claude G Negrier, Doris Quon, Michael Recht, Jean François Schved, Amy D Shapiro, Robert Sidonio, Alok Srivastava, Oleksandra Stasyshyn, Kateryna V Vilchevska, Michael Wang, Guy Aaron Young, W Allan Alexander, Ahmad Al-Sabbagh, Daniel Bonzo, Christopher Macie, Thomas A Wilkinson, Craig Kessler
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia : the official journal of the World Federation of Hemophilia 27 (6) (2021)
Beatrice Nolan, Johnny N Mahlangu, Ingrid Pabinger, Guy Aaron Young, Barbara A Konkle, Chris Barnes, Keiji Nogami, Elena Santagostino, K John Pasi, Liane Khoo, Bent Winding, Huixing Yuan, Joachim Fruebis, Dan Rudin, Johannes Oldenburg
Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia : the official journal of the World Federation of Hemophilia 26 (3) (2020)
Glenn F Pierce, K John Pasi, Donna Coffin, Radoslaw Kaczmarek, David Lillicrap, Johnny N Mahlangu, Dawn Rottellini, Thomas Sannié, Alok Srivastava, Thierry VandenDriessche, Alain Weill, null null
Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia : the official journal of the World Federation of Hemophilia 26 (3) (2020)
Johnny N Mahlangu, Victor Blanchette, Robert Klamroth
Redefining prophylaxis in the modern era. Haemophilia : the official journal of the World Federation of Hemophilia (2020)
Alok Srivastava, Elena Santagostino, Alison Dougall, Steve Kitchen, Megan Sutherland, Steven W Pipe, Manuel D Carcao, Johnny N Mahlangu, Margaret V Ragni, Jerzy Windyga, Adolfo Llinás, Nicholas J Goddard, Richa Mohan, Pradeep Mathew Poonnoose, Brian M Feldman, Sandra Zelman Lewis, H Marijke van den Berg, Glenn F Pierce, null null
WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia : the official journal of the World Federation of Hemophilia (2020)
K John Pasi, Kathelijn Fischer, Margaret V Ragni, Roshni Daniel Kulkarni, Margareth C Ozelo, Johnny N Mahlangu, Amy D Shapiro, Stephanie P'Ng, Hervé Chambost, Beatrice Nolan, Carolyn Bennett, Tadashi Matsushita, Bent Winding, Joachim Fruebis, Huixing Yuan, Dan Rudin, Johannes Oldenburg
Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study. Haemophilia : the official journal of the World Federation of Hemophilia 26 (6) (2020)
Maria Elisa Mancuso, Johnny N Mahlangu, Robert Sidonio, Peter Trask, Marianne Uguen, Tiffany Chang, Midori Shima, Guy Aaron Young, Johannes Oldenburg, Sylvia von Mackensen
Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia : the official journal of the World Federation of Hemophilia 26 (6) (2020)
Johnny N Mahlangu, Maria Fernanda Lopez Fernandez, Elena Santagostino, Shadan Lalezari, Despina Tseneklidou-Stoeter, Horst Beckmann, Nikki Church
BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years. European journal of haematology 104 (6) (2020)
Rebecca Kruse-Jarres, Johannes Oldenburg, Elena Santagostino, Midori Shima, Christine L Kempton, Craig M Kessler, Michaela Lehle, Sammy Chebon, Nives Selak Bienz, Elina Asikanius, Johnny N Mahlangu
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia : the official journal of the World Federation of Hemophilia 25 (2) (2019)
Johnny N Mahlangu, Johannes Oldenburg, Michael U Callaghan, Midori Shima, Maria Elisa Mancuso, Peter Trask, Michael Recht, Claudia Garcia, Renchi Yang, Michaela Lehle, Harrison Macharia, Elina Asikanius, Gallia G Levy, Rebecca Kruse-Jarres, Sylvia von Mackensen
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia : the official journal of the World Federation of Hemophilia 25 (3) (2019)
Johnny N Mahlangu
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 32 (6) (2019)
Cedric Hermans, Johnny N Mahlangu, J Booth, Helmut Schütz, E Santagostino, Guy Aaron Young, H-Y Lee, K N Steinitz-Trost, V Blanchette, E Berntorp
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. Haemophilia : the official journal of the World Federation of Hemophilia 24 (3) (2018)
Johnny N Mahlangu, Johannes Oldenburg, Michael U Callaghan, Midori Shima, Elena Santagostino, Maggie Moore, Michael Recht, Claudia Garcia, Renchi Yang, Michaela Lehle, Harrison Macharia, Elina Asikanius, Gallia G Levy, Rebecca Kruse-Jarres
Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. Haemophilia : the official journal of the World Federation of Hemophilia 24 (6) (2018)
Johnny N Mahlangu, Guy Aaron Young, Cedric Hermans, V Blanchette, E Berntorp, E Santagostino
Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia : the official journal of the World Federation of Hemophilia 24 (3) (2018)
Johannes Oldenburg, Manuel D Carcao, Steven R Lentz, Johnny N Mahlangu, Maria Elisa Mancuso, Tadashi Matsushita, Claude Négrier, Wan Hui Ong Clausen, Silke Ehrenforth, Guy Aaron Young
Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials. Haemophilia : the official journal of the World Federation of Hemophilia 24 (6) (2018)
Johannes Oldenburg, Johnny N Mahlangu, Willem Bujan, Peter Trask, Michael U Callaghan, Guy Aaron Young, Elina Asikanius, Flora Peyvandi, Elena Santagostino, Rebecca Kruse-Jarres, Claude Negrier, Craig Kessler, Jin Xu, Jerzy Windyga, Midori Shima, Sylvia von Mackensen
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia : the official journal of the World Federation of Hemophilia 25 (1) (2018)
Pratima Chowdary, P Angchaisuksiri, J Dimsits, Alfonso Iorio, Kaan Kavakli, Steven R Lentz, Johnny N Mahlangu, A McCarthy, C Kessler
Haemophilia clinical care and research needs: Assessing priorities. Haemophilia : the official journal of the World Federation of Hemophilia 24 (4) (2018)